50685-26-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(Cyanomethyl)benzoic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex organic molecules that can exhibit therapeutic properties.
Used in Dye Industry:
In the dye industry, 4-(cyanomethyl)benzoic acid is utilized as a building block for the production of various dyes, owing to its capacity to be incorporated into the molecular structures that determine color and stability.
Used in Organic Compounds Synthesis:
4-(Cyanomethyl)benzoic acid is used as a versatile intermediate for the synthesis of other organic compounds, highlighting its importance in organic chemistry for creating a wide array of products with different applications.
Used in Research and Development:
4-(CYANOMETHYL)BENZOIC ACID is also an important constituent in research and development settings, where it is used to explore new chemical reactions, develop novel materials, and understand the fundamental principles of organic chemistry.

InChI:InChI=1/C9H7NO2/c10-6-5-7-1-3-8(4-2-7)9(11)12/h1-4H,5H2,(H,11,12)

Upstream product

• 6232-88-8 4-bromomethylbenzoic Acid 
• 143-33-9 sodium cyanide 
• 1642-81-5 p-(chloromethyl)benzoic acid 
• 64-17-5 ethanol 
• 151-50-8 potassium cyanide 
• 905966-41-8 2-(4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)acetonitrile 
• 124-38-9 carbon dioxide 
• 99-94-5 p-Toluic acid 
• 51628-12-7 4-iodophenylacetonitrile 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 
• 83901-88-6 4-cyanomethylbenzoic acid ethyl ester 
• 876-31-3 4-(cyanomethyl)benzonitrile 

Downstream Products

• 52787-17-4 α-carbamoyl-p-toluic acid 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 
• 80589-49-7 4-cyanomethylbenzoyl chloride 
• 501-89-3 4-(carboxymethyl)benzoic acid 
• 409344-82-7 6-amino-3-butyl-5-(4-cyanomethylbenzoyl)amidouracil 
• 409344-84-9 1-butyl-8-[4-(cyanomethyl)phenyl]xanthine 
• 120352-92-3 4-Cyanomethyl-N,N-dimethyl-benzamide 
• 208921-82-8 4-Cyanomethyl-N,N-dimethyl-thiobenzamide 
• 208921-80-6 4-(cyanomethyl)-N,N-diethylbenzamide 
• 208921-83-9 4-Cyanomethyl-N,N-diethyl-thiobenzamide 
• 52787-14-1 methyl 4-(2-methoxy-2-oxoethyl)benzoate 
• 153802-44-9 4-(1-Methoxycarbonyl-but-3-enyl)-benzoic acid methyl ester 
• 184918-80-7 4-[1-(2,4-Diamino-5-methyl-pyrido[2,3-d]pyrimidin-6-ylmethyl)-but-3-enyl]-benzoic acid 
• 184918-78-3 4-[1-Carboxy-1-(2,4-diamino-5-methyl-pyrido[2,3-d]pyrimidin-6-ylmethyl)-but-3-enyl]-benzoic acid 

Relevant academic research and scientific papers

Constructing, deconstructing, and reconstructing ternary supermolecules

A hypothesis-driven protocol comprising precise and predictable molecular recognition events based upon an electrostatic view of competing hydrogen-bond interactions is proposed and subsequently employed in the construction of ternary co-crystals. The Royal Society of Chemistry.

Green synthesis method of aromatic acid

The invention discloses a green synthesis method of aromatic acid. Nickel-catalyzed carbonyl insertion is carried out on aryl iodine in the presence of formate, acid anhydride, a phosphine ligand andan organic solvent by using a nickel catalyst to obtain the aromatic acid. Efficient catalytic conversion is realized by utilizing the cheap nickel catalyst, the reaction conditions are mild, and theoperation is simple.

Nickel-catalyzed carboxylation of aryl iodides with lithium formate through catalytic CO recycling

A protocol for the Ni-catalyzed carboxylation of aryl iodides with formate has been developed with good functional group compatibility for the synthesis of a variety of aromatic carboxylic acids under mild conditions. The reaction tolerates other functionalities for cross-coupling, such as aryl bromide, aryl chloride, aryl tosylate, and aryl pinacol boronate. The reaction proceeds through a carbonylation process with in situ generated carbon monoxide in the presence of a catalytic amount of acetic anhydride and lithium formate, avoiding the use of gaseous CO. The strategy of CO recycling in catalytic amounts is critical for the success of the reaction.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Phenyl 1, 2 - isoxazole or phenyl 1, 2 - pyrazole compound and use thereof (by machine translation)

The invention discloses the following formula of phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds with use. Through the biological activity tests show that, the compound inhibiting heat shock protein 90 activity. Therefore, the invention phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds can be used as a heat shock protein 90 inhibitor for the treatment of cancer. (by machine translation)

Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors

HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)phenyl)isoxazol-5-yl)cyclopropanecarboxamide (108) showed high affinity for binding to HSP90 (FP binding assay, IC50 Combining double low line 0.030 μM) and inhibited the proliferation of various human cancer cell lines with averaging GI50 about 88 nM. Compound 108 exhibited its functional inhibition of HSP90 by depleting key signaling pathways and concomitantly elevating of HSP70 and HSP27 in U-87MG cells. Further in vivo studies showed that compound 108 strongly suppressed the tumor growth of human glioblastoma xenograft model U-87MG with T/C Combining double low line 18.35% at 50 mg/kg q3w/2.5w. Moreover, compound 108 also exhibited good pharmacokinetic properties. Together, our study implicates that compound 108 is a promising candidate of HSP90 inhibitor and is currently advanced to preclinical study.

NEW 2-AMINOTHIADIAZOLE DERIVATIVES

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein:. L represents a direct bond or a -S(O)2- group, ? n is an integer having a value from 0 to 2, ? R1 represents a pyridyl group or an imidazo[1,2-α]pyridinyl group, wherein the pyridyl group is substituted with one or more substituents selected from halogen atoms, a hydroxy group, a C1-4 alkyl group and a C1-4 alkoxy group, or ? R1 represents a group of formula: wherein:. Ra and Rb independently represent a hydrogen atom, halogen atom or a linear or branched C1-4, alkyl group,. Rc represents a hydroxy group, a linear or branched C1-4 alkyl group or C1-4 alkoxy group wherein the alkyl and the alkoxy groups independently are optionally substituted with one or more substituents selected from hydroxy group, cyano group and-NR'R" groups and wherein R' represents a hydrogen atom or a linear or branched C1-4 alkyl group, R" represents a hydrogen atom or a linear or branched C1-4 alkyl group optionally substituted with a hydroxycarbonyl group; or R' and R" together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic ring optionally substituted with a hydroxycarbonyl group.. R2 represents a pyridyl group, a C3-6 cycloalkyl group or a phenyl group which is optionally substituted with one or more substituents selected from halogen atoms, cyano group, and C1-4 alkoxy group; and. R3 represents a C3-6 cycloalkyl group, a C3-6 cycloalkyl-C1-2 alkyl group or a linear or branched C2-4 alkyl group optionally substituted with one or more substituents selected from halogen atoms and C1-2 alkoxy group.

New 2-aminothiadiazole derivatives

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein: ? L represents a direct bond or a -S(O)2- group, ? n is an integer having a value from 0 to 2, ? R1 represents a pyridyl group or an imidazo[1,2-a]pyridinyl group, wherein the pyridyl group is substituted with one or more substituents selected from halogen atoms, a hydroxy group, a C1-4 alkyl group and a C1-4 alkoxy group, or ? R1 represents a group of formula: wherein: o Ra and Rb independently represent a hydrogen atom, halogen atom or a linear or branched C1-4 alkyl group, o Rc represents a hydroxy group, a linear or branched C1-4 alkyl group or C1-4 alkoxy group wherein the alkyl and the alkoxy groups independently are optionally substituted with one or more substituents selected from hydroxy group, cyano group and-NR'R" groups and wherein ■ R' represents a hydrogen atom or a linear or branched C1-4 alkyl group, ■ R" represents a hydrogen atom or a linear or branched C1-4 alkyl group optionally substituted with a hydroxycarbonyl group; or ■ R' and R" together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic ring optionally substituted with a hydroxycarbonyl group. ? R2 represents a pyridyl group, a C3-6 cycloalkyl group or a phenyl group which is optionally substituted with one or more substituents selected from halogen atoms, cyano group, and C1-4 alkoxy group; and ? R3 represents a C3-6 cycloalkyl group, a C3-6 cycloalkyl-C1-2 alkyl group or a linear or branched C2-4 alkyl group optionally substituted with one or more substituents selected from halogen atoms and C1-2 alkoxy group.

OLIGOTHIOPHENES AND USES THEREOF IN PHOTOVOLTAIC DEVICES

Compounds of formula (I) wherein EWG is an electron withdrawing group or combination of groups, R1 and R2 are each independently selected from the group consisting of alkyl, aromatic or heteroaromatic groups, or R1 and R2 may together comprise a linked alkyl, aromatic or heteroaromatic group. R3 and R4 are each independently selected from the group consisting of alkyl, alkoxy or H, or R3 and R4 may together comprise a divalent alkyl group, a divalent alkoxy or alkyldioxy group, or R3 and R4 may together comprise a heterocyclic, heteroaromatic or aromatic group linked or fused to the thiophene group and n is an integer between 2 and 10. The compounds are capable of charge transportation and have application in organic photovoltaic devices such as dye sensitised solar cells.

Copper(I)-catalyzed carboxylation of aryl- and alkenylboronic esters

(Chemical Equation Presented) The copper(I)-catalyzed carboxylation reaction of aryl- and alkenylboronic esters proceeded smoothly under CO 2 to give the corresponding carboxylic acid in good yield. This reaction showed wide generality with higher functional group tolerance compared to the corresponding Rh(I)-catalyzed reaction.